494 OR502, a best-in-class anti-LILRB2 antibody that enhances both innate and adaptive anti-tumor immune responses

oleh: Peter Probst, Kevin Green, Huyen Dinh, Francisco Zapata, Darbie Whitman, Tom Graddis, Meghan Zuck, Ray Fox, Myriam N Bouchlaka, Tatyana Pisarenko, Elsa L Hay, Gajendra Naika, Jacob Heit, Kamal D Puri

Format: Article
Diterbitkan: BMJ Publishing Group 2023-11-01

Deskripsi

No description available for this item.